Times are tough, but activist investors are still finding some diamonds among the rough.Both Carl Icahn and Eastbourne Capital have made five nominations to the board of directors of Amylin Pharmaceuticals ( AMLN) in attempts to possibly sell the company to a larger biotechnology firm. As of their latest filings, Carl Icahn owns approximately 8.3% of Amylin, and Eastbourne Capital owns approximately 12.5%. San Diego-based Amylin Pharmaceuticals is the maker of the diabetes drug Byetta, with a joint 50-50 partnership with Eli Lilly ( LLY - Get Report), thus making Lilly the most likely candidate to buy Amylin. To read more about this and other activist situations, visit Stockpickr.com.
More from Investing
Cadence Design Jumps in After-Hours Trading on Earnings Beat
Revenue and EPS top analyst expectations for the third quarter.
Howard Hughes Corp. Plunges on CEO Departure, HQ Move and Asset Sales Plan
Shares fall after real estate developer names a new CEO and releases reorganization plan that includes $2 billion in assets sales.
WeWork's Valuation Sinks to $8 Billion Under Rescue Proposal: Report
Office space rental operator facing possible takeover by SoftBank after $40 billion in valuation disappears since botched IPO.